BINEX (A053030) Stock Overview
Operates as a pharmaceutical company in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
A053030 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
BINEX Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩15,050.00 |
| 52 Week High | ₩23,250.00 |
| 52 Week Low | ₩12,800.00 |
| Beta | 0.73 |
| 1 Month Change | 2.87% |
| 3 Month Change | -6.29% |
| 1 Year Change | -26.59% |
| 3 Year Change | 35.59% |
| 5 Year Change | -41.55% |
| Change since IPO | 692.11% |
Recent News & Updates
BINEX Co., Ltd.'s (KOSDAQ:053030) Price In Tune With Revenues
Aug 20
Would BINEX (KOSDAQ:053030) Be Better Off With Less Debt?
May 15Recent updates
BINEX Co., Ltd.'s (KOSDAQ:053030) Price In Tune With Revenues
Aug 20Would BINEX (KOSDAQ:053030) Be Better Off With Less Debt?
May 15What You Can Learn From BINEX Co., Ltd.'s (KOSDAQ:053030) P/S After Its 25% Share Price Crash
Mar 05Here's Why BINEX (KOSDAQ:053030) Can Afford Some Debt
Feb 13Revenues Tell The Story For BINEX Co., Ltd. (KOSDAQ:053030) As Its Stock Soars 35%
Jan 08BINEX Co., Ltd. (KOSDAQ:053030) May Have Run Too Fast Too Soon With Recent 28% Price Plummet
Nov 18Does BINEX (KOSDAQ:053030) Have A Healthy Balance Sheet?
Oct 23Revenues Not Telling The Story For BINEX Co., Ltd. (KOSDAQ:053030) After Shares Rise 25%
Sep 01Subdued Growth No Barrier To BINEX Co., Ltd. (KOSDAQ:053030) With Shares Advancing 32%
Jul 01BINEX Co., Ltd.'s (KOSDAQ:053030) 30% Share Price Plunge Could Signal Some Risk
Apr 17We Think That There Are More Issues For BINEX (KOSDAQ:053030) Than Just Sluggish Earnings
Mar 22BINEX Co., Ltd.'s (KOSDAQ:053030) Shares Climb 37% But Its Business Is Yet to Catch Up
Feb 26Does BINEX (KOSDAQ:053030) Have A Healthy Balance Sheet?
Mar 18If You Had Bought BINEX (KOSDAQ:053030) Stock A Year Ago, You Could Pocket A 253% Gain Today
Jan 28Are BINEX Co., Ltd.'s (KOSDAQ:053030) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Dec 24Shareholder Returns
| A053030 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 0.5% | 1.8% | 5.4% |
| 1Y | -26.6% | 23.7% | 73.4% |
Return vs Industry: A053030 underperformed the KR Pharmaceuticals industry which returned 23.7% over the past year.
Return vs Market: A053030 underperformed the KR Market which returned 73.4% over the past year.
Price Volatility
| A053030 volatility | |
|---|---|
| A053030 Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.9% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A053030 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A053030's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1957 | 650 | Hyuk-Jong Lee | www.bi-nex.co.kr |
BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. The company engages in cell line and process development, and analytical method production development. It is also involved in cell cultivation and microbial fermentation modalities process production.
BINEX Co., Ltd. Fundamentals Summary
| A053030 fundamental statistics | |
|---|---|
| Market cap | ₩487.27b |
| Earnings (TTM) | -₩7.70b |
| Revenue (TTM) | ₩165.64b |
Is A053030 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A053030 income statement (TTM) | |
|---|---|
| Revenue | ₩165.64b |
| Cost of Revenue | ₩121.02b |
| Gross Profit | ₩44.61b |
| Other Expenses | ₩52.32b |
| Earnings | -₩7.70b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -241.84 |
| Gross Margin | 26.93% |
| Net Profit Margin | -4.65% |
| Debt/Equity Ratio | 42.5% |
How did A053030 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/06 10:33 |
| End of Day Share Price | 2026/01/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BINEX Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Heeyoung Lee | Daishin Securities Co. Ltd. |
| Sung Hwan Choi | Kyobo Securities Co., Ltd |
| Mi Hyun Kim | Morgan Stanley |